Clinical trials: Metastatic
Metastatic Lesions in Vertebral Bodies
Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)
The purpose of this study is to evaluate treating painful metastatic lesions in vertebral bodies with pathologic fractures with targeted radiofrequency ablation (t-RFA) and vertebral augmentation (VA) prior to or following…
- Trial name
- STARRT (NCT02225223)
- Testing
- STAR™ Tumor Ablation System, StabiliT® Vertebral Augmentation System
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- Merit Medical Systems, Inc.
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with…
- Trial name
- NCT01199068
- Testing
- CS-7017, Erlotinib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Squamous Cell Carcinoma of the Head and Neck
Expansion Trial for Axitinib In Head And Neck Cancer
This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02762513
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non Small Cell Lung Cancer
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
- Trial name
- NCT00890825
- Testing
- AZD6244, docetaxel
- Where
- 63 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well omacetaxine mepesuccinate, cytarabine, and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT02029417
- Testing
- cytarabine, omacetaxine mepesuccinate, decitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
This phase II trial studies the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer.
- Conditions
- Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma
- Trial name
- NCT03146650
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and…
- Conditions
- HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02774291
- Testing
- Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Metastatic Urothelial Cancer
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
This is a single arm open label multi-institutional phase II trial of olaparib monotherapy in subjects with metastatic urothelial cancer harboring somatic DNA damage response (DDR) alterations.
- Trial name
- NCT03448718
- Testing
- Olaparib
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Matthew Galsky
Metastatic Breast Cancer
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line…
- Trial name
- CLEOPATRA (NCT00567190)
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 322 sites in United States, Argentina and 24 more
- Volunteers
- 808 people
- Sponsor
- Genentech, Inc.
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT04269213
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Nonsquamous Non-small-cell Lung
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976323
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab.
- Trial name
- NCT00567879
- Testing
- Panobinostat, Trastuzumab
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic…
- Trial name
- NCT00544908
- Testing
- dasatinib, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Prostate Cancer
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
The purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in…
- Trial name
- NCT03600350
- Testing
- pTVG-HP, Nivolumab, GM-CSF
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Thyroid Cancer
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
The purpose of this study is to find out if the drug AZD6244 can improve the radioactive iodine uptake by the patient's metastatic thyroid cancer.
- Trial name
- NCT00970359
- Testing
- AZD6244
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastasis Spine, Metastasis to Bone
OsteoCool Tumor Ablation Post-Market Study
This study evaluates the effectiveness of the Medtronic OsteoCool™ RF Ablation System.
- Trial name
- OPuS One (NCT03249584)
- Testing
- OsteoCool™ RF Ablation
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 218 people
- Sponsor
- MedtronicNeuro
Gastric Cancer
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to evaluate progression-free survival in participants with gastric or gastroesophageal junction cancer who have had disease progression following first-line therapy who undergo treatment with…
- Trial name
- NCT01983878
- Testing
- Ramucirumab
- Where
- 11 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.